This is the authors' abstract. We don't add key points for this paper.
, respectively). Here, we demonstrate the potential application of mutational signatures to tumor sequencing workflows to improve the identification of biallelic MUTYH carriers.
No takes yet. Share an insight, caveat, or question.
Georgeson et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: